Individualized Cost-Effectiveness Analysis
暂无分享,去创建一个
[1] Erry,et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. , 1995, The New England journal of medicine.
[2] Joshua P Cohen,et al. Switching prescription drugs to over the counter , 2004, BMJ : British Medical Journal.
[3] Michael Doherty,et al. Lifestyle interventions for knee pain in overweight and obese adults aged ≥45: economic evaluation of randomised controlled trial , 2009, BMJ : British Medical Journal.
[4] John Cairns,et al. Evaluation of modernisation of adult critical care services in England: time series and cost effectiveness analysis , 2009, BMJ : British Medical Journal.
[5] A. Mehrez,et al. Economics, health and health economics: HYEs versus QALYs , 1993 .
[6] J. Lau,et al. The impact of high-risk patients on the results of clinical trials. , 1997, Journal of clinical epidemiology.
[7] M Meisner,et al. Statistical inference for cost-effectiveness ratios. , 1997, Health economics.
[8] Stephen W. Sorensen,et al. The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance , 2005, Annals of Internal Medicine.
[9] Richard L Kravitz,et al. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. , 2004, The Milbank quarterly.
[10] M. Sculpher,et al. Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost effectiveness study , 2009, BMJ : British Medical Journal.
[11] Douglas K. Owens,et al. A Method for Estimating the Cost- Effectiveness of Incorporating Patient Preferences into Practice Guidelines , 1994, Medical decision making : an international journal of the Society for Medical Decision Making.
[12] B. Gage,et al. Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation , 2009, Annals of Internal Medicine.
[13] C. Dewa,et al. Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions , 2012, PharmacoEconomics.
[14] B. Gage,et al. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. , 1998, Stroke.
[15] A. Willan. On the probability of cost-effectiveness using data from randomized clinical trials , 2001, BMC medical research methodology.
[16] S. Goldie,et al. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States , 2009, BMJ : British Medical Journal.
[17] Kilkon Ko,et al. Procuring Organ Donors as a Health Investment: How Much Should We Be Willing to Spend? , 2004, Transplantation.
[18] Martina Garau,et al. Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study , 2004, BMJ : British Medical Journal.
[19] David M Kent,et al. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal , 2010, Trials.
[20] Kirsten Bibbins-Domingo,et al. Comparing Impact and Cost-Effectiveness of Primary Prevention Strategies for Lipid-Lowering , 2009, Annals of Internal Medicine.
[21] M. Gold. Cost-effectiveness in health and medicine , 2016 .
[22] R. Luce. Utility of Gains and Losses: Measurement-Theoretical and Experimental Approaches , 2000 .
[23] M. Mclaughlin. Healthcare policy implications of heterogeneity of treatment effects. , 2007, The American journal of medicine.
[24] A. Mehrez,et al. Quality-adjusted Life Years, Utility Theory, and Healthy-years Equivalents , 1989, Medical decision making : an international journal of the Society for Medical Decision Making.
[25] Anthony O'Hagan,et al. The probability of cost-effectiveness , 2002, BMC medical research methodology.
[26] R. Kravitz,et al. Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment. , 2007, The American journal of medicine.
[27] Les M Irwig,et al. An evidence based approach to individualising treatment , 1995, BMJ.
[28] D. Owens,et al. Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. , 2009 .
[29] S. Gilbody,et al. Benefits and harms of direct to consumer advertising: a systematic review , 2005, Quality and Safety in Health Care.
[30] N. Latimer,et al. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis , 2009, BMJ : British Medical Journal.
[31] Douglas K Owens,et al. High-Value, Cost-Conscious Health Care: Concepts for Clinicians to Evaluate the Benefits, Harms, and Costs of Medical Interventions , 2011, Annals of Internal Medicine.
[32] S. Palmer,et al. Screening for postnatal depression in primary care: cost effectiveness analysis , 2009, BMJ : British Medical Journal.
[33] E. Elbasha. Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach. , 2005, Health economics.
[34] Dan Greenberg,et al. Bias in published cost effectiveness studies: systematic review , 2006, BMJ : British Medical Journal.
[35] J. Ioannidis,et al. Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou test , 2011, Canadian Medical Association Journal.
[36] A. Briggs,et al. Trying to do better than average: a commentary on 'statistical inference for cost-effectiveness ratios'. , 1997, Health Economics.
[37] B. O'brien,et al. Building uncertainty into cost-effectiveness rankings: portfolio risk-return tradeoffs and implications for decision rules. , 2000, Medical care.
[38] B. Watts,et al. Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis , 2009, BMJ : British Medical Journal.
[39] A. Mehrez,et al. Economics, health and health economics: HYEs (healthy-years equivalent) versus QALYs (quality-adjusted live-year) , 1993, Journal of health economics.
[40] M. Liang,et al. Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents , 2009, Annals of Internal Medicine.
[41] Caroline F Wright,et al. Regulating direct-to-consumer genetic tests: What is all the fuss about? , 2011, Genetics in Medicine.
[42] William D. Schafer,et al. Gender differences in risk taking: A meta-analysis. , 1999 .
[43] Paola Sapienza,et al. Gender differences in financial risk aversion and career choices are affected by testosterone , 2009, Proceedings of the National Academy of Sciences.